Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 3,044 Shares of Company Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 3,044 shares of the stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $90.03, for a total transaction of $274,051.32. Following the completion of the sale, the executive vice president owned 29,276 shares of the company’s stock, valued at approximately $2,635,718.28. The trade was a 9.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ryan Savitz also recently made the following trade(s):

• On Thursday, November 12th, Ryan Savitz sold 17,724 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.56, for a total transaction of $1,605,085.44.
• On Monday, November 9th, Ryan Savitz sold 100,713 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.54, for a total transaction of $9,118,555.02.
• On Tuesday, November 10th, Ryan Savitz sold 2,561 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.14, for a total transaction of $230,848.54.

Dianthus Therapeutics Stock Up 3.6%

Dianthus Therapeutics stock opened at $92.48 on Friday. Dianthus Therapeutics, Inc. has a 12 month low of $34.29 and a 12 month high of $117.88. The stock has a market cap of $5.21 billion, a P/E ratio of -23.18 and a beta of 1.47. The company’s fifty day simple moving average is $88.77 and its 200-day simple moving average is $86.36.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.13. The business had revenue of $1.21 million during the quarter, compared to analyst estimates of $0.46 million. Dianthus Therapeutics had a negative return on equity of 19.68% and a negative net margin of 7,436.50%. On average, equities research analysts expect that Dianthus Therapeutics, Inc. will post -3.55 earnings per share for the current fiscal year.

Dianthus Therapeutics News Summary

Here’s some of the latest news about DNTH:

• Positive Sentiment: HC Wainwright was reported to have a bullish estimate for Dianthus’s FY2026 earnings, although the available report does not provide the estimate or its reasoning. Article: HC Wainwright Has Bullish Estimate for DNTH FY2026 Earnings
• Positive Sentiment: The company’s latest reported quarter beat analyst expectations for both adjusted loss per share and revenue, offering a supportive backdrop. Dianthus Therapeutics company information
• Negative Sentiment: EVP Ryan Savitz sold a combined 124,042 shares in transactions from November 9–12, worth about $11.2 million. The sales represent a significant reduction in his reported stake and could unsettle investors, though the reports do not give a reason for the transactions. Article: Dianthus Therapeutics EVP Sells 17,724 Shares of Stock

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DNTH. Citigroup initiated coverage on Dianthus Therapeutics in a research note on Friday, September 4th. They set a “buy” rating and a $156.00 price target for the company. Raymond James Financial reissued a “strong-buy” rating and issued a $134.00 price target on shares of Dianthus Therapeutics in a research note on Thursday, November 5th. JPMorgan Chase & Co. assumed coverage on Dianthus Therapeutics in a report on Friday, September 11th. They issued an “overweight” rating and a $135.00 price objective on the stock. Wedbush increased their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Finally, Truist Financial raised their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $128.77.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in Dianthus Therapeutics during the second quarter worth $401,990,000. Wellington Management Group LLP raised its stake in Dianthus Therapeutics by 24.4% during the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock valued at $314,849,000 after purchasing an additional 634,099 shares during the last quarter. Jennison Associates LLC bought a new stake in Dianthus Therapeutics in the 1st quarter valued at $40,713,000. Assenagon Asset Management S.A. boosted its holdings in Dianthus Therapeutics by 160.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock valued at $64,474,000 after purchasing an additional 451,597 shares during the period. Finally, Spruce Street Capital LP acquired a new stake in Dianthus Therapeutics in the 2nd quarter worth $34,587,464. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.